Omer, Israel

Eliezer Adar

This inventor holds 1 USPTO granted patent. Top assignee: Chemagis Ltd.. Active years: 2009.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Eliezer Adar. Retrieved from https://idiyas.com/inventor/eliezer-adar-maoupngj

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2009

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Eliezer Adar: Innovator in Pharmaceutical Chemistry

Introduction

Eliezer Adar is a notable inventor based in Omer, Israel. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of processes for synthesizing important compounds.

Latest Patents

Eliezer Adar holds a patent for "Processes for the preparation of rocuronium bromide and intermediates thereof." This patent discloses a novel process for preparing (2β,3α,5α,16β,17β)-17-acetoxy-3-hydroxy-2-(4-morpholinyl)-16-(1-pyrrolidinyl) androstane, which is a known intermediate in the synthesis of the skeletal muscle relaxant rocuronium bromide. This innovation is crucial for enhancing the efficiency of producing this important pharmaceutical agent.

Career Highlights

Eliezer Adar is associated with Chemagis Ltd., where he applies his expertise in pharmaceutical processes. His work has contributed to advancements in the synthesis of critical compounds used in medical applications.

Collaborations

Eliezer has collaborated with notable colleagues, including Iosef Manascu and David Sondack. These partnerships have fostered a collaborative environment that enhances innovation and research in their field.

Conclusion

Eliezer Adar's contributions to pharmaceutical chemistry, particularly through his patent on rocuronium bromide synthesis, highlight his role as an innovator in the industry. His work continues to impact the development of essential medical compounds.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…